Format

Send to

Choose Destination
Leuk Lymphoma. 2018 May;59(5):1121-1126. doi: 10.1080/10428194.2017.1369070. Epub 2017 Aug 30.

A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.

Author information

1
a Department of Internal Medicine IV , Klinikum Wels-Grieskirchen , Wels , Austria.
2
b Department of Internal Medicine V (Hematology and Oncology) , Innsbruck Medical University , Innsbruck , Austria.
3
c Department of Internal Medicine , Landeskrankenhaus Feldkirch , Feldkirch , Austria.
4
d Department of Internal Medicine I , Krankenhaus der Elisabethinen , Linz , Austria.
5
e Department of Hematology and OncologyIII , Hanusch Hospital , Vienna , Austria.
6
f Ludwig-Boltzmann Cluster Oncology, Medical University of Vienna , Vienna , Austria.
7
g Department of Internal Medicine I , Krankenhaus der Barmherzigen Schwestern , Linz. Austria.
8
h Department of Internal Medicine I, Division of Hematology and Hemostaseology , Medical University of Vienna , Vienna , Austria.
9
i 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Laboratory for Immunological and Molecular Cancer Research , Paracelsus Medical University Hospital Salzburg , Salzburg , Austria.

Abstract

According to former classification systems chronic myelomonocytic leukemia (CMML) is listed within myelodysplastic syndromes (MDS). Therefore data regarding treatment of CMML is largely derived from MDS trials. Two published studies suggest efficacy of lenalidomide in a proportion of patients with CMML, but the number of patients included was very low. We initiated this phase I trial with lenalidomide in patients with CMML. Primary objective of the current study was to determine the maximum tolerated dose (MTD). Secondary objectives were safety, tolerability and response. Twenty patients were enrolled and received lenalidomide using a classical 3 + 3 design. Lenalidomide 5 mg daily was confirmed as MTD. Best response achieved was partial remission in one patient and stable disease in nine patients. Lack of response with primary progressive disease was seen in three patients. Lenalidomide had a good toxicity profile in this study with thrombocytopenia being the main toxicity observed. Efficacy needs to be confirmed in further trials.

KEYWORDS:

Chronic myelomonocytic leukemia (CMML); clinical trial; lenalidomide

PMID:
28853315
DOI:
10.1080/10428194.2017.1369070
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center